These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 37724763)

  • 21. Transmission and Drug Resistance Genotype of Multidrug-Resistant or Rifampicin-Resistant Mycobacterium tuberculosis in Chongqing, China.
    Zhao B; Liu C; Fan J; Ma A; He W; Hu Y; Zhao Y
    Microbiol Spectr; 2022 Oct; 10(5):e0240521. PubMed ID: 36214695
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment cascade for patients with multidrug- or rifampicin-resistant tuberculosis and associated factors with patient attrition in southeastern China: a retrospective cohort study.
    Chen B; Chen X; Ren Y; Peng Y; Wang F; Zhou L; Xu B
    J Infect Public Health; 2023 Jul; 16(7):1073-1080. PubMed ID: 37209611
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Current Treatment of Drug-Resistant Tuberculosis in Children.
    Schaaf HS; Hughes J
    Indian J Pediatr; 2024 Aug; 91(8):806-816. PubMed ID: 37995068
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ongoing challenges to understanding multidrug- and rifampicin-resistant tuberculosis in children
    McQuaid CF; Cohen T; Dean AS; Houben RMGJ; Knight GM; Zignol M; White RG
    Eur Respir J; 2021 Feb; 57(2):. PubMed ID: 32855219
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Scaling up target regimens for tuberculosis preventive treatment in Brazil and South Africa: An analysis of costs and cost-effectiveness.
    Nsengiyumva NP; Campbell JR; Oxlade O; Vesga JF; Lienhardt C; Trajman A; Falzon D; Den Boon S; Arinaminpathy N; Schwartzman K
    PLoS Med; 2022 Jun; 19(6):e1004032. PubMed ID: 35696431
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tuberculosis Diagnosis and Preventive Monotherapy Among Children and Adolescents Exposed to Rifampicin-Resistant Tuberculosis in the Household.
    Apolisi I; Cox H; Tyeku N; Daniels J; Mathee S; Cariem R; Douglas-Jones B; Ngambu N; Mudaly V; Mohr-Holland E; Isaakidis P; Pfaff C; Furin J; Reuter A
    Open Forum Infect Dis; 2023 Mar; 10(3):ofad087. PubMed ID: 36910692
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Failure of chemoprophylaxis with standard antituberculosis agents in child contacts of multidrug-resistant tuberculosis cases.
    Sneag DB; Schaaf HS; Cotton MF; Zar HJ
    Pediatr Infect Dis J; 2007 Dec; 26(12):1142-6. PubMed ID: 18043453
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 1-Year Incidence of Tuberculosis Infection and Disease Among Household Contacts of Rifampin- and Multidrug-Resistant Tuberculosis.
    Krishnan S; Wu X; Kim S; McIntire K; Naini L; Hughes MD; Dawson R; Mave V; Gaikwad S; Sanchez J; Mendoza-Ticona A; Gonzales P; Comins K; Shenje J; Fontain SN; Omozoarhe A; Mohapi L; Lalloo UG; Garcia Ferreira AC; Mugah C; Harrington M; Shah NS; Hesseling AC; Churchyard G; Swindells S; Gupta A;
    Clin Infect Dis; 2023 Sep; 77(6):892-900. PubMed ID: 37227925
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tuberculosis in household contacts of multidrug-resistant tuberculosis patients.
    Grandjean L; Crossa A; Gilman RH; Herrera C; Bonilla C; Jave O; Cabrera JL; Martin L; Escombe AR; Moore DA
    Int J Tuberc Lung Dis; 2011 Sep; 15(9):1164-9, i. PubMed ID: 21943839
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tuberculosis burden in households of patients with multidrug-resistant and extensively drug-resistant tuberculosis: a retrospective cohort study.
    Becerra MC; Appleton SC; Franke MF; Chalco K; Arteaga F; Bayona J; Murray M; Atwood SS; Mitnick CD
    Lancet; 2011 Jan; 377(9760):147-52. PubMed ID: 21145581
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Factors contributing to the high prevalence of multidrug-resistance/Rifampicin-resistance in patients with tuberculosis: an epidemiological cross sectional and qualitative study from Khabarovsk krai region of Russia.
    Bykov I; Dyachenko O; Ratmanov P; Liu H; Liang L; Wu Q
    BMC Infect Dis; 2022 Jul; 22(1):612. PubMed ID: 35831812
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Progress in research of prophylactic therapy in contacts of rifampicin-resistant tuberculosis patients].
    Wang Z; Wang WJ; Ding XY; Lu P; Zhu LM; Liu Q; Lu W
    Zhonghua Liu Xing Bing Xue Za Zhi; 2023 Mar; 44(3):470-476. PubMed ID: 36942344
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rifampicin-Monoresistant Tuberculosis Is Not the Same as Multidrug-Resistant Tuberculosis: a Descriptive Study from Khayelitsha, South Africa.
    Salaam-Dreyer Z; Streicher EM; Sirgel FA; Menardo F; Borrell S; Reinhard M; Doetsch A; Cudahy PGT; Mohr-Holland E; Daniels J; Dippenaar A; Nicol MP; Gagneux S; Warren RM; Cox H
    Antimicrob Agents Chemother; 2021 Oct; 65(11):e0036421. PubMed ID: 34460307
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Estimating the impact of a novel drug regimen for treatment of tuberculosis: a modeling analysis of projected patient outcomes and epidemiological considerations.
    Kendall EA; Malhotra S; Cook-Scalise S; Denkinger CM; Dowdy DW
    BMC Infect Dis; 2019 Sep; 19(1):794. PubMed ID: 31500572
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of Xpert MTB/RIF on the treatment of multi-drug-resistant or rifampicin-resistant tuberculosis screened out from re-treatment pulmonary tuberculosis patients, a prospective cohort study.
    Wang P; Gu J; Yang J; Yang C; Wu X; Yu F; Fan L
    Ann Palliat Med; 2020 Mar; 9(2):239-246. PubMed ID: 32233619
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Value of pyrazinamide for composition of new treatment regimens for multidrug-resistant Mycobacterium tuberculosis in China.
    Xia H; van den Hof S; Cobelens F; Zhou Y; Zhao B; Wang S; Zhao Y
    BMC Infect Dis; 2020 Jan; 20(1):19. PubMed ID: 31910878
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High rate of successful treatment outcomes among childhood rifampicin/multidrug-resistant tuberculosis in Pakistan: a multicentre retrospective observational analysis.
    Naz F; Ahmad N; Wahid A; Ahmad I; Khan A; Abubakar M; Khan SA; Khan A; Latif A; Ghafoor A
    BMC Infect Dis; 2021 Dec; 21(1):1209. PubMed ID: 34863099
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MDR-TB treatment as prevention: The projected population-level impact of expanded treatment for multidrug-resistant tuberculosis.
    Kendall EA; Azman AS; Cobelens FG; Dowdy DW
    PLoS One; 2017; 12(3):e0172748. PubMed ID: 28273116
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rifampin-resistant/multidrug-resistant Tuberculosis in Alberta, Canada: Epidemiology and treatment outcomes in a low-incidence setting.
    Edwards BD; Edwards J; Cooper R; Kunimoto D; Somayaji R; Fisher D
    PLoS One; 2021; 16(2):e0246993. PubMed ID: 33592031
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk factors for the occurrence of multidrug-resistant tuberculosis among patients undergoing multidrug-resistant tuberculosis treatment in East Shoa, Ethiopia.
    Desissa F; Workineh T; Beyene T
    BMC Public Health; 2018 Apr; 18(1):422. PubMed ID: 29606112
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.